Navigation Links
Teva to Acquire Barr
Date:7/18/2008

eneric products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions (including the pending acquisition of Bentley Pharmaceuticals, Inc.), potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F, Barr's Annual Report on Form 10-K and their other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and neither Teva nor Ivax undertakes no obligation to update publicly or revise any forward- looking statement, whether as a result of new information, future developments or otherwise.

This communication is being made in respect of the proposed merger involving Teva and Barr. In connection with the proposed merger, Teva will be filing a registration statement on Form F-4 containing a proxy statement/prospectus for the stockholders of Barr, and Barr will be filing a prox
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Neogen Acquires Kane Enterprises
4. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
7. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
8. NSF International Acquires David Begg Associates
9. United BioSource Acquires Caro Research, Leader in Simulation Modeling
10. Groupe Novasep to Acquire PharmaChem Technologies (Grand Bahama) Ltd
11. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
(Date:7/25/2014)... 2014 WABC Radio show out of New ... Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder and ... therapy in pets. Dr. Harman first visited the show ... therapy for pets suffering from osteoarthritis and other degenerative diseases, ... industry forward. , Young has invited Dr. Harman back to ...
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
... are succumbing to infection with canine distemper virus (CDV), a ... authors of a study published in mBio , the ... Pressure from poaching, decimation of their prey base, and ... called Siberian tigers) to fewer than 500. In the study, ...
... clinicians have an interest in how the cells of our ... to grow, to heal, to transmit information internally, to mount ... necessary for survival. But if cell mobility is unregulated, tumors ... multi-disciplinary study by University of Pennsylvania researchers has now illuminated ...
... 2013  Local Pearle Vision licensee, Theresa Ayers , has added ... with her husband, Ronald Ayers , the husband-and-wife team assumed ... Everhard Road N.W. Theresa Ayers has been with Pearle Vision, one ... licensed optical brands, for more than three decades. She began her ...
Cached Biology News:Canine distemper virus: An emerging disease in rare Amur tigers 2Multi-disciplinary Penn research identifies protein required for cell movement 2Multi-disciplinary Penn research identifies protein required for cell movement 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 4Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 5
... GyroTwister GX-1000 3-D Shaker , ... shaking motion of the GyroTwister GX-1000 is ... ideal for general mixing as well as ... speed is continuously adjustable across a broad ...
...
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
...
Biology Products: